Your search
Results 3 resources
-
Introduction: Letermovir is a cytomegalovirus (CMV) terminase complex inhibitor approved for prophylaxis of CMV infection and disease in adult CMV-seropositive allogeneic hematopoietic cell transplantation (allo-HCT) recipients (R+). We report pharmacokinetics (PK), safety, and efficacy of letermovir in adolescent (12–18 years) allogeneic HCT recipients from an ongoing clinical study. Methods: In this phase 2b, multicenter, open-label study (NCT03940586), 28...
-
CMV infection is a common complication in patients undergoing hematopoietic-cell transplantation. The incidence of CMV infection was 23 percentage points lower with prophylactic letermovir, a CMV–terminase complex inhibitor, than with placebo, with only low-level toxic effects.
Filter by our tag
ORGANISMS
HEME-ONC AND CELLULAR THERAPIES
- Heme-onc prophylaxis (1)
- PEDIATRIC (1)